Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
Sandoz And Amgen Resolve Patent Disputes Over FDA-Approved Denosumab Biosimilars In The US
山德士和安进在美国解决有关美国食品药品管理局批准的Denosumab生物仿制药的专利纠纷
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
山德士与安进达成协议，解决与其美国denosumab生物仿制药有关的所有专利诉讼
- Agreement clears path for launch of Jubbonti and Wyost on May 31, 2025 or earlier under certain circumstances
- Jubbonti and Wyost are first and only FDA-approved biosimilars to and interchangeable with Prolia* and Xgeva*
- Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy
- 协议为在某些情况下于2025年5月31日或更早推出Jubbonti和Wyost扫清了道路
- Jubbonti 和 Wyost 是美国食品药品管理局批准的第一款也是唯一一款可与 Prolia* 和 Xgeva* 互换的生物仿制药
- 预期的推出进一步强化了山德士生物仿制药产品组合并推进了增长战略